Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2011, Vol. 22 ›› Issue (4): 212-216 doi: 10.13538/j.1001-8042/nst.22.212-216

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Therapeutic safety evaluation of sodium glycididazole combined with 131I radiotherapy for differentiated thyroid carcinoma

SUN Wenwei GU Xinquan# GAO Shi BAI Lin CUI Qu MA Qingjie Wang Qing Zhao Guoqing   

  1. China-Japan Union Hospital,Jilin University,Changchun 130033,China
PDF ShareIt Export Citation
SUN Wenwei, GU Xinquan, GAO Shi, BAI Lin, CUI Qu, MA Qingjie, Wang Qing, Zhao Guoqing. Therapeutic safety evaluation of sodium glycididazole combined with 131I radiotherapy for differentiated thyroid carcinoma.Nuclear Science and Techniques, 2011, 22(4): 212-216     doi: 10.13538/j.1001-8042/nst.22.212-216

Abstract:

To evaluate safety and therapeutic efficacy of sodium glycididazole (CMNa) combined with 131I radiotherapy for differentiated thyroid carcinoma (DTC),the 60 patients of DTC therapeutic protocols were selected and divided into 3 groups of the DTC 4.44 GBq 131I,DTC 3.70 GBq 131I,and combination of DTC 3.70 GBq 131I with CMNa,and the 20 patients of Graves' Disease were selected as the control group.Peripheral blood was sampled at 131I pre-treatment of 1 day,and 131I post-treatment of 7,91,and 182 days,thus analyzing lymphocyte micronucleus scores and karyotyping profiles.Compared with the control group,the lymphocyte micronucleus and chromosome mutation rates in 131I treated DTC increased after post-treatment of 7 days,recovered after post-treatment of 91 days,and did not bounce after post-treatment of 182 days.The micronucleus and chromosome mutation rates in the combination of DTC 3.70 GBq 131I with CMNa showed less significant variation than other treated DTC groups.Our results demonstrate that micronucleus assay and karyotyping analysis are favorable to evaluate 131I radiotherapy for DTC.The combination of the CMNa with 131I radiotherapy was safe for DTC patients without affecting the long-term therapeutic outcomes.

Key words: Radioactive nuclide, Iodine, Thyroid, Radiosensitizer, Metaphase